Abstract
Hepatitis C virus (HCV) is the leading cause of hepatocellular carcinoma (HCC). While direct-acting antiviral (DAA) therapy efficiently eradicates HCV infection, epidemiological studies show that sustained virological response (SVR) following anti-HCV treatment reduces, but does not eliminate, the risk for HCC. We have recently demonstrated that HCV infection induces genome-wide epigenetic changes that reprogram host gene expression and persist as “epigenetic signature” following virus eradication by DAAs. We suggest that this epigenetic signature underlie the residual risk for HCC post-SVR. Here, we provide a methodology to study the HCV-induced epigenetic signature. We describe a ChIP-seq protocol to evaluate changes in epigenome profile following HCV infection, its cure with DAA, and after treatment with epigenetic modifier inhibitor. We also describe evaluation of changes in the gene expression profile using RNA-seq. The integration between detected alterations in epigenetic marks and gene expression allows for identification of biological processes that are involved in HCV-driven oncogenesis before and after cure.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gronbaek K, Hother C, Jones PA (2007) Epigenetic changes in cancer. APMIS 115:1039–1059
Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8:286–298
Ribich S, Harvey D, Copeland RA (2017) Drug discovery and chemical biology of cancer epigenetics. Cell Chem Biol 24:1120–1147
Gramling S, Rogers C, Liu G, Reisman D (2011) Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy. Oncogene 30:3289–3294
Halley-Stott RP, Gurdon JB (2013) Epigenetic memory in the context of nuclear reprogramming and cancer. Brief Funct Genomics 12:164–173
Lilley CE, Chaurushiya MS, Weitzman MD (2010) Chromatin at the intersection of viral infection and DNA damage. Biochim Biophys Acta 1799:319–327
Knipe DM, Lieberman PM, Jung JU, McBride AA, Morris KV, Ott M et al (2013) Snapshots: chromatin control of viral infection. Virology 435:141–156
D'Ambrosio R, Della Corte C, Colombo M (2015) Hepatocellular carcinoma in patients with a sustained response to anti-hepatitis C therapy. Int J Mol Sci 16:19698–19712
Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB (2017) Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 153(996–1005):e1001
Ono A, Goossens N, Finn RS, Schmidt WN, Thung SN, Im GY et al (2017) Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature. Hepatology 66:1344–1346
Nakagawa S, Wei L, Song WM, Higashi T, Ghoshal S, Kim RS et al (2016) Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition. Cancer Cell 30:879–890
Iwasaki W, Miya Y, Horikoshi N, Osakabe A, Taguchi H, Tachiwana H et al (2013) Contribution of histone N-terminal tails to the structure and stability of nucleosomes. FEBS Open Bio 3:363–369
Rothbart SB, Strahl BD (2014) Interpreting the language of histone and DNA modifications. Biochim Biophys Acta 1839:627–643
Bannister AJ, Kouzarides T (2011) Regulation of chromatin by histone modifications. Cell Res 21:381–395
Faure AJ, Schmidt D, Watt S, Schwalie PC, Wilson MD, Xu H et al (2012) Cohesin regulates tissue-specific expression by stabilizing highly occupied cis-regulatory modules. Genome Res 22:2163–2175
Polak P, Karlic R, Koren A, Thurman R, Sandstrom R, Lawrence MS et al (2015) Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature 518:360–364
Furey TS (2012) ChIP-seq and beyond: new and improved methodologies to detect and characterize protein-DNA interactions. Nat Rev Genet 13:840–852
Pundhir S, Poirazi P, Gorodkin J (2015) Emerging applications of read profiles towards the functional annotation of the genome. Front Genet 6:188
Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, Holbert MA et al (2010) Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol 17:471–482
Rusyn I, Lemon SM (2014) Mechanisms of HCV-induced liver cancer: what did we learn from in vitro and animal studies? Cancer Lett 345:210–215
Li Q, Zhang YY, Chiu S, Hu Z, Lan KH, Cha H et al (2014) Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycle. PLoS Pathog 10:e1004163
Iqbal J, McRae S, Banaudha K, Mai T, Waris G (2013) Mechanism of hepatitis C virus (HCV)-induced osteopontin and its role in epithelial to mesenchymal transition of hepatocytes. J Biol Chem 288:36994–37009
Chen Y, Chen J, Wang H, Shi J, Wu K, Liu S et al (2013) HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. PLoS Pathog 9:e1003248
Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L et al (2011) EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 17:589–595
Zhang Q, Wei L, Yang H, Yang W, Yang Q, Zhang Z et al (2016) Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection. Cancer Lett 371:107–116
Luna JM, Scheel TK, Danino T, Shaw KS, Mele A, Fak JJ et al (2015) Hepatitis C virus RNA functionally sequesters miR-122. Cell 160:1099–1110
Yamane D, McGivern DR, Wauthier E, Yi M, Madden VJ, Welsch C et al (2014) Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. Nat Med 20:927–935
Neufeldt CJ, Joyce MA, Levin A, Steenbergen RH, Pang D, Shields J et al (2013) Hepatitis C virus-induced cytoplasmic organelles use the nuclear transport machinery to establish an environment conducive to virus replication. PLoS Pathog 9:e1003744
Zona L, Lupberger J, Sidahmed-Adrar N, Thumann C, Harris HJ, Barnes A et al (2013) HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe 13:302–313
Li Q, Sodroski C, Lowey B, Schweitzer CJ, Cha H, Zhang F et al (2016) Hepatitis C virus depends on E-cadherin as an entry factor and regulates its expression in epithelial-to-mesenchymal transition. Proc Natl Acad Sci U S A 113:7620–7625
Li Q, Pene V, Krishnamurthy S, Cha H, Liang TJ (2013) Hepatitis C virus infection activates an innate pathway involving IKK-alpha in lipogenesis and viral assembly. Nat Med 19:722–729
Steenbergen RH, Joyce MA, Thomas BS, Jones D, Law J, Russell R et al (2013) Human serum leads to differentiation of human hepatoma cells, restoration of very-low-density lipoprotein secretion, and a 1000-fold increase in HCV Japanese fulminant hepatitis type 1 titers. Hepatology 58:1907–1917
El-Shamy A, Eng FJ, Doyle EH, Klepper AL, Sun X, Sangiovanni A et al (2015) A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene. J Hepatol 63:1323–1333
Yi M, Ma Y, Yates J, Lemon SM (2007) Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J Virol 81:629–638
Gal-Tanamy M, Zemel R, Bachmatov L, Jangra RK, Shapira A, Villanueva RA et al (2010) Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies. Antivir Res 88:95–106
Acknowledgment
The authors acknowledge grant support from the Leona M. and Harry B. Helmsley Charitable Trust Grant #2012PG-ISL013 and Israel Cancer Association #20160120. The authors thank Prof. Izhak Haviv (Bar-Ilan University), Prof. Assam El-Osta (Monash University), and Dr. Antony Kaspi (Monash University) for their insight and helpful discussions.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Perez, S., Gal-Tanamy, M. (2019). Studying the Hepatitis C Virus-Induced Epigenetic Signature After Cure with Direct-Acting Antivirals. In: Law, M. (eds) Hepatitis C Virus Protocols . Methods in Molecular Biology, vol 1911. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8976-8_13
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8976-8_13
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8975-1
Online ISBN: 978-1-4939-8976-8
eBook Packages: Springer Protocols